

RECEIVED  
CENTRAL FAX CENTER

001

NOV 10 2005

PATENT  
Docket No. 275.0010 0101IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): MUNN et al. )  
Serial No.: 10/780,797 )  
Confirmation No.: 1508 )  
Filed: February 17, 2004 )  
For: USE OF INHIBITORS OF INDOLEAMINE-2, 3-DIOXYGENASE IN  
COMBINATION WITH OTHER THERAPEUTIC MODALITIES )

Group Art Unit: 1614  
Examiner: Delacroix Muirhei,  
Cybille

FACSIMILE TRANSMISSION TO THE PTO

Commissioner for Patents  
Mail Stop Amendment  
P.O. Box 1450  
Alexandria, VA 22313-1450

FAX NUMBER: (571) 273-8300  
Total Pages (including cover page): 41  
Time: 3:15 pm (Central Time)  
(Transmission must be complete by  
midnight eastern time.)

The following papers are being transmitted to the Patent and Trademark Office by facsimile transmission: SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (2 PGS)  
1449 FORM (1 PG)  
COPIES OF 3 DOCUMENTS LISTED ON 1449 FORM ( 37 TOTAL PGS)

X Small Entity Status is entitled to be asserted in the above-identified application.

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895.

Muetting, Raasch & Gebhardt, P.A.  
Customer Number: 26813

November 10, 2005  
Date

By: Nancy A. Johnson  
Nancy A. Johnson  
Reg. No. 47,266  
Direct Dial (612)305-4723

**CERTIFICATE UNDER 37 C.F.R. §1.8:** The undersigned hereby certifies that this Facsimile Cover Sheet and the paper(s), as described hereinabove, are being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office addressed to the Commissioner for Patents, Mail Stop Amendment, P.O. Box 1450, Alexandria, VA 22313-1450, on this 10 day of NOV, 2005, at 3:15 pm (Central Time).

11-10-05  
Date

Signature: Sandy Truehart  
Name: Sandy Truehart

If you do not receive all pages, please contact us at (612)305-1220 (ph) or (612)305-1228 (fax).

NOV 10 2005

PATENT  
Docket No. 275.0010 0101IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): MUNN et al. ) Group Art Unit: 1614  
Serial No.: 10/780,797 )  
Confirmation No.: 1508 )  
Filed: February 17, 2004 )  
For: USE OF INHIBITORS OF INDOLEAMINE-2, 3-DIOXYGENASE IN  
COMBINATION WITH OTHER THERAPEUTIC MODALITIES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. § 609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form is respectfully requested. Pursuant to the provisions of M.P.E.P. § 609, Applicants further request that a copy of the 1449 form, marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

It is believed that no fee is due, as this Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895.

Supplemental Informatin Disclosure Statement

Page 2 of 2

Serial No. 10/780,797

Filed: February 17, 2004

USE OF INHIBITORS OF INDOLEAMINE-2, 3-DIOXYGENASE IN COMBINATION WITH OTHER  
THERAPEUTIC MODALITIES

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

## CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper is being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office, addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 10 day of Nov, 2005, at 3:15 pm (Central Time).

Sandy Truehart  
Name: Sandy Truehart

November 10, 2005  
Date

Respectfully submitted for  
MUNN et al.

By

Mueting, Raasch &amp; Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Phone: (612)305-1220

Facsimile: (612)305-1228

Customer Number 26813

By: Nancy A. Johnson  
Nancy A. Johnson  
Reg. No. 47,266  
Direct Dial (612)305-4723

OMB No. 0651-0011

Page 1 of 1

<b>INFORMATION DISCLOSURE STATEMENT</b>	Atty. Docket No.: 275.00100101	Serial No.: 10/780,797
	Applicant(s): MUNN et al.	Confirmation No.: 1508
	Application Filing Date: 02/17/04	Group: 1614
	Information Disclosure Statement mailed: November <u>10</u> , 2005	

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	NONE					

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Copy Enclosed	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		NONE						

**OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)**

Examiner Initial	Copy Enclosed	Document Description
	✓	Habara-Ohkubo et al., (1993) "Establishment of an Antitoxoplasma State by Stable Expression of Mouse Indoleamine 2,3-Dioxygenase," <i>Infection and Immunity</i> , Vol. 61 (5), 1810-1813
	✓	Kaufman et al. (1995) "Xenotransplantation," <i>Annu. Rev. Immunol.</i> , Vol. 13:339-367
	✓	Takikawa et al., (1990) "IFN- $\gamma$ Is the Inducer of Indoleamine 2,3-Dioxygenase in Allografted Tumor Cells Undergoing Rejection," <i>J. Immunol.</i> , Vol. 145 (4), 1246-1250

<b>EXAMINER</b>	<b>Date Considered</b>
<small>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	